p increased by 1.7%-points to Novo Nordisk ® Diabetes value market leadership expansion driven by the GLP-1 franchise Diabetes care sales grew by 14% with global value market share increase driven by GLP-1 market share gains in both IO and NAO Insulin value market share has slightly increased from 44.0% to 44.2% in the last 12 months GLP-1 value market share has increased by 3.6%-points in the last 12 months, driven by: • Ozempic ® launches and uptake in 75 countries • Rybelsus ® uptake in North America Operations and launches in International Operations • Global GLP-1 volume growth of ~44% • GLP-1 is only 4% of total diabetes prescriptions
Download PDF file